#### Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOC Form 4	EN INC								
June 13, 200	)5								
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION							-	OMB APPROVAL	
Washington, D.C. 20549						NOMB Number:	3235-0287		
Check th if no lon subject t Section Form 4 o Form 5 obligatio may con <i>See</i> Instr	ger o 16. or Filed pur ons tinue.	suant to Section a) of the Public	<b>CHANGES IN BENEFICIAL OWNERSHIP OF</b> <b>SECURITIES</b> ection 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Sectio of the Investment Company Act of 1940					Expires: January 31, 2005 Estimated average burden hours per response 0.5	
1(b).									
(Print or Type	Responses)								
			2. Issuer Name <b>and</b> Ticker or Trading Symbol			5. Relationship of Reporting Person(s) to Issuer			
			IUNOGEN	INC [IM	GN]	(Check all applicable)			
(Last) (First) (Middle) C/O IMMUNOGEN, INC., 128 SIDNEY STREET			3. Date of Earliest Transaction (Month/Day/Year) 06/09/2005			X Director 10% Owner X Officer (give title Other (specify below) below) Chief Executive Officer			
(Street)			4. If Amendment, Date Original			6. Individual or Joint/Group Filing(Check			
CAMBRID	GE, MA 02139	Filed(	Filed(Month/Day/Year)			Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip) T	able I - Non-	Derivative	Securities A	cquired, Disposed	of. or Beneficia	llv Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. f Transactic Code	4. Securit mAcquired Disposed (Instr. 3, 4	ies (A) or of (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Rep	port on a separate line	for each class of s	securities bene	•	•	or indirectly.	ction of	SEC 1474	
				Perso				14/4	

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Am
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Sec
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

#### Edgar Filing: IMMUNOGEN INC - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	2		
				Code V	(A) (D)	) Date Exercisable	Expiration Date	Title A o N o
Non-qualified stock option (right to buy)	\$ 5.35	06/09/2005		А	56,308	06/09/2006 <u>(2)</u>	06/09/2015	Common stock
Incentive stock option (right to buy)	\$ 5.35	06/09/2005		А	18,692	06/09/2007 <u>(1)</u>	06/09/2015	Common stock

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
SAYARE MITCHEL C/O IMMUNOGEN, INC. 128 SIDNEY STREET CAMBRIDGE, MA 02139	Х		Chief Executive Officer			

### Signatures

/s/ Karleen M. Oberton, power of attorney in fact.

\*\*Signature of Reporting Person

06/13/2005 Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Exercisable as to 1 on June 09, 2007 and 18,691 on June 09, 2008.
- (2) Exercisable as to 25,000 on June 09, 2006, 24,999 on June 09, 2007, and 6,309 on June 09, 2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.